• GMP
    • Reviews
    • Subscription
    • Allotment

    Valiant Laboratories IPO GMP, Guidance, Subscription & listing @ Chanakyanipothi.com, Valiant Laboratories IPOIndia`s Oldest Investment & IPO website. 
    A legacy of 31 Years.
    Most Trusted by Investors across India.

    Valiant Laboratories IPO Listing Review:
    The scrip issued at Rs. 160 is listed at  Rs. 162.15, marginal premium of Rs 2.15 over its issue price.

    Why should you apply Valiant Laboratories IPO? Review: 
    The company is an Active Pharmaceutical Ingredient (“API”) / Bulk Drug manufacturing company, with steady and good profitability track-record. The offer price is quite reasonable. The IPO size is also very small in mainboard category. Huge oversubscription expected, in spite of large number of IPOs. Apply

    Valiant Laboratories IPO Grey Market Premium  
    Premium: Rs.20 Grey market premium dpboss
    Kostak Rs. –
    BHni/SHni Subject to price Rs. 20500

    Subscription Status of Valiant Laboratories IPO 

    On 3 October 2023 @ 5.00 (Day 4) Closed
    Review: Trend improved on Day 4
    QIB:             2178030  Shares    20.83 T
    NII(10L+):    1088999  Shares   63.62 T
    NII (<10L)      544501  Shares   78.64 T
    NII (Total)    1633500  Shares    73.63 T
    RII:               3811500  Shares   16.04 T
    Total:           7623030  Shares    29.75 T

     

    Who is the promoter of Valiant Laboratories IPO? 
    SHANTILAL SHIVJI VORA AND DHANVALLABH VENTURES LLP 

    What is the business of Valiant Laboratories?

    Valiant Laboratories is an Active Pharmaceutical Ingredient (“API”) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. Paracetamol , is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol has several applications such as usage in treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold and fever. We manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers. Paracetamol was initially approved by the U.S. Food and Drug Administration (“US FDA”) in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms. Paracetamol is often found combined with other drugs in many over the counter (“OTC”) allergy medications, cold medications, sleep medications, pain relievers, and other products.

    Its manufacturing facility is located at Plot nos. L-13 and L-30, Tarapur Industrial Area, Boisar, Palghar
    – 401506, in the state of Maharashtra, India which is spread over an aggregate parcel of land admeasuring about 2,000 sq. mts. with an aggregate annual total installed capacity of 9,000 MT per annum. The Manufacturing Facility employs modern machinery and equipment to ensure smooth flow of operations. It is holding certificate of good manufacturing practices (GMP) for manufacture and sale of bulk drugs / API and ISO 9001:2015 certification.

    Its quality control team monitors the manufacturing process at all stages from initial testing stage for incoming raw material to the final product prior to packing. Within its Manufacturing Facility located at Tarapur Industrial Area, Palghar, Maharashtra it aso has an in-house R&D infrastructure.
    The Company is promoted by Shantilal Shivji Vora, Director and Dhanvallabh Ventures LLP.
    Shantilal Shivji Vora has over 45 years of experience in chemical and pharmaceutical industry

    The company, through its wholly owned subsidiary, Valiant Advanced Sciences Private Limited intend to establish a greenfield project at Saykha Industrial Area, Bharuch, Gujarat, which shall be spread over an aggregate parcel of land admeasuring about 57,766 sq. mtrs. (“Proposed Facility”) which shall venture into manufacture of speciality chemicals such as ketene and diketene derivative products. One of these products namely, acetic anhydride is used as a raw material in the process of manufacture of paracetamol.

    To get more information about the company, click www.valiantlabs.in

    What is the object of Valiant Laboratories IPO?
    The Company proposes to utilise the Net Proceeds towards funding the following objects:
    1. Investment in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited
    for part-financing its capital expenditure requirements in relation to the setting up of a
    manufacturing facility for speciality chemicals at Saykha Industrial Area, Bharuch, Bharuch,
    Gujarat (“Proposed Facility”);
    2. Investment in VASPL for funding its working capital requirements; and
    3. General corporate purposes

    Valiant Laboratories IPO GMP, details & review

    Valiant Laboratories IPO Details 
    IPO opens on  27 September ,2023 
    IPO closes on  3 October ,2023 
    Issue Type Book Built Issue IPO
    Issue Size 10890000 Sh /Rs 152.46 Cr
    * Fresh Issue 10890000 Sh /Rs 152.46 Cr
    * Offer for Sale 
       
    Face Value per share: Rs. 10
    Price Band  Rs. 133-140
    Retail Discount  Rs 0 per share
    Employee discount  Rs. 0 per share
    Retail Lot Size  105 Shares
    Listing will at  BSE, NSE
    Shares offered to Shares Rs. in Cr
    QIB (50 %)  5445000 76.23
    NII (15 %)  1633500 22.87
    RII (35 %)  3811500 53.36
    Employees  X
    Total Shares  10890000 152.46
    Retail portion will be oversubscribed by  X Forms.
    How to apply in Valiant Laboratories IPO? Rs.
    Min Retail Application 105 Sh 14,700
    Max Retail Application  1365 Sh 191,100
    Small HNI (Min) application  1470 Sh 205,800
    Small HNI (Max) application 7140 Sh 999,600
    Big HNI Application 7245 Sh 1014,300
    Timetable of Valiant Laboratories IPO
    IPO opens on 27 September 2023
    IPO Closes on 3 October 2023
    IPO Allotment on  5 October 2023
    Unblocking of ASBA  6 October 2023
    Credit of Shares 6 October 2023
    Listing on 6 October 2023
    Registered Office of Valiant Laboratories
    104, Udyog Kshetra, Mulund Goregaon Link Road, Mulund West, Mumbai- 400080, Maharashtra
    Lead Managers of Valiant Laboratories IPO
    Unistone Capital Pvt ltd
    Registrar to IPO
    Link Intime India Private Limited
    Valiant Laboratories IPO Financial & Analytical Ratios
    Year Total Income Net Profit EPS RoNW
      Rs. in Cr Rs.in Cr Rs. %
    2020-21 183.78 30.59 10.8 34.54
    2021-22 293.47 27.49 9.52 38.48
    2022-23  338.77 29.00 8.91 28.86
    Book Value of the Share on 31.03.2023 Rs. 30.86    
    BV of the Share after the IPO Rs. 0    
    Offer Price at Cap Rs.  140    
    Ratio Analysis
    Upper Price /last EPS 15.71
    Price/Book Value Ratio 4.54
    Price/BV after IPO  ?

    Valiant Laboratories IPO GMP, details & Guidance
    Which are the companies which can be compared with Tata Technologies? Study Peer Comparison.

    As on date of RHP Total Income Rs. Face  PE
      Income Value Ratio of
      Rs. In Cr Rs  
    The IPO Company 334 10 15.71
    Granules India 4512 1 83.10
    Jagsonpal Pharma 236.71 1 40.92
           
       
    X

    # This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.

    >>Go to Mainboard IPOs Section: Click
    >>Go to SME IPOs Section: Click
    >>
    Get Good Staff or Job, Click: Staffavailable.com
    >>Interested in Used Automobiles or vintage cars? Click: BigGaddi.com
    >>Get solid Guidance on Mutual fund Investments, Click: ChanakyaMFGuidance.com
    >>Study Stock Research Reports, Click: AnalysisLibrary.com
    >>
    Interested in Crossword Puzzles? Click: Magajmari.com

    One thought on “Valiant Laboratories listed @ Rs. 162.15

    Leave a Reply

    Your email address will not be published. Required fields are marked *